This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cesana, G. C. Articles by Kaufman, H. L. Search for Related Content PubMed PubMed Citation Articles by Cesana, G. C. Articles by Kaufman, H. L. Social Bookmarking                            What's this?

Characterization of CD4⁺CD25⁺ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma

From the Tumor Immunology Laboratory, Department of Surgery and Biostatistics, Columbia University Medical Center, New York, NY

Address reprint requests to Howard L. Kaufman, MD, Columbia University Medical Center, 177 Fort Washington Ave, New York, NY 10032; e-mail: hlk2003{at}columbia.edu

PURPOSE: To characterize the number and functional status of CD4⁺CD25⁺ regulatory T cells (Tregs) in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) treated with high-dose bolus interleukin-2 (IL-2).

PATIENTS AND METHODS: Patients with MM or RCC treated with high-dose bolus IL-2 (600,000 IU/kg every 8 hours) at a single center provided pre- and post-treatment whole blood specimens. Peripheral blood mononuclear cells were isolated by Ficoll density gradient centrifugation, separated into cellular subsets, and analyzed by flow cytometry or used for in vitro proliferation assays.

RESULTS: Between September 2003 and July 2005 57 patients were enrolled in the study with 48 patients available for analysis (45 MM, 12 RCC). Tregs were defined as CD4⁺CD25^hi T cells, and this subset was significantly elevated in the cancer patients compared with normal donors (7.75% v 2.24%). The CD4⁺CD25^hi T-cell pool in the patients constitutively expressed intracellular FoxP3, CTLA-4, and produced high amounts of IL-10. The Tregs were CCR7⁺ with 50% representing naïve and 50% central-memory T cells. The cells were functionally suppressive in mixed in vitro proliferation assays. Following IL-2 administration, the number and frequency of Tregs increased in patients with progressive disease but returned to normal levels in patients with objective clinical responses.

CONCLUSION: The number of Tregs, defined as CD4⁺CD25^hi T cells is increased in patients with MM and RCC. High-dose IL-2 resulted in a significant decrease of Tregs in those patients achieving an objective clinical response to IL-2 therapy.

Supported by Grant No. RO1 93696 from the National Institutes of Health and the Chiron Corporation.

Presented in part at the Masir Congress on Measurement of Antigen-Specific Immune Responses, Courmayeur, Italy, January 26-29, 2005 and at the 58th Annual Cancer Symposium of the Society of Surgical Oncology, Atlanta, GA, March 3-5, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Sabatino, S. Kim-Schulze, M. C. Panelli, D. Stroncek, E. Wang, B. Taback, D. W. Kim, G. DeRaffele, Z. Pos, F. M. Marincola, et al. Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy J. Clin. Oncol., June 1, 2009; 27(16): 2645 - 2652. [Abstract] [Full Text] [PDF]

				P. LISSONI, F. BRIVIO, L. FUMAGALLI, G. MESSINA, S. MEREGALLI, G. PORRO, F. ROVELLI, L. VIGORE, E. TISI, and G. D'AMICO Effects of the Conventional Antitumor Therapies Surgery, Chemotherapy, Radiotherapy and Immunotherapy on Regulatory T Lymphocytes in Cancer Patients Anticancer Res, May 1, 2009; 29(5): 1847 - 1852. [Abstract] [Full Text] [PDF]

				J. S. Ko, A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. A. Rayman, L. Wood, J. Garcia, et al. Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients Clin. Cancer Res., March 15, 2009; 15(6): 2148 - 2157. [Abstract] [Full Text] [PDF]

				T. Nicholaou, L. M. Ebert, I. D. Davis, G. A. McArthur, H. Jackson, N. Dimopoulos, B. Tan, E. Maraskovsky, L. Miloradovic, W. Hopkins, et al. Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma Clin. Cancer Res., March 15, 2009; 15(6): 2166 - 2173. [Abstract] [Full Text] [PDF]

				I. D. Davis, B. Brady, R. F. Kefford, M. Millward, J. Cebon, B. K. Skrumsager, U. Mouritzen, L. T. Hansen, K. Skak, D. Lundsgaard, et al. Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial Clin. Cancer Res., March 15, 2009; 15(6): 2123 - 2129. [Abstract] [Full Text] [PDF]

				H. K. Jensen, F. Donskov, M. Nordsmark, N. Marcussen, and H. von der Maase Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma Clin. Cancer Res., February 1, 2009; 15(3): 1052 - 1058. [Abstract] [Full Text] [PDF]

				G. Wieczorek, A. Asemissen, F. Model, I. Turbachova, S. Floess, V. Liebenberg, U. Baron, D. Stauch, K. Kotsch, J. Pratschke, et al. Quantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue Cancer Res., January 15, 2009; 69(2): 599 - 608. [Abstract] [Full Text] [PDF]

				J. H. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond, A. Golshayan, L. Wood, P. Elson, J. Garcia, R. Dreicer, et al. Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients Clin. Cancer Res., October 15, 2008; 14(20): 6674 - 6682. [Abstract] [Full Text] [PDF]

				R. J. Lechleider, P. M. Arlen, K.-Y. Tsang, S. M. Steinberg, J. Yokokawa, V. Cereda, K. Camphausen, J. Schlom, W. L. Dahut, and J. L. Gulley Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant Clin. Cancer Res., August 15, 2008; 14(16): 5284 - 5291. [Abstract] [Full Text] [PDF]

				B. Kavanagh, S. O'Brien, D. Lee, Y. Hou, V. Weinberg, B. Rini, J. P. Allison, E. J. Small, and L. Fong CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion Blood, August 15, 2008; 112(4): 1175 - 1183. [Abstract] [Full Text] [PDF]

				J. Yokokawa, V. Cereda, C. Remondo, J. L. Gulley, P. M. Arlen, J. Schlom, and K. Y. Tsang Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer Clin. Cancer Res., February 15, 2008; 14(4): 1032 - 1040. [Abstract] [Full Text] [PDF]

				M. D. Behrens, W. M. Wagner, C. J. Krco, C. L. Erskine, K. R. Kalli, J. Krempski, E. A. Gad, M. L. Disis, and K. L. Knutson The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity Blood, February 1, 2008; 111(3): 1472 - 1479. [Abstract] [Full Text] [PDF]

				R. L. VanOosten and T. S. Griffith Activation of Tumor-Specific CD8+ T Cells after Intratumoral Ad5-TRAIL/CpG Oligodeoxynucleotide Combination Therapy Cancer Res., December 15, 2007; 67(24): 11980 - 11990. [Abstract] [Full Text] [PDF]

				K. Leon, K. Garcia, J. Carneiro, and A. Lage How Regulatory CD25+CD4+ T Cells Impinge on Tumor Immunobiology: The Differential Response of Tumors to Therapies J. Immunol., November 1, 2007; 179(9): 5659 - 5668. [Abstract] [Full Text] [PDF]

				M. D. McCarter, J. Baumgartner, G. A. Escobar, D. Richter, K. Lewis, W. Robinson, C. Wilson, B. E. Palmer, and R. Gonzalez Immunosuppressive Dendritic and Regulatory T Cells are Upregulated in Melanoma Patients Ann. Surg. Oncol., October 1, 2007; 14(10): 2854 - 2860. [Abstract] [Full Text] [PDF]

				D. F. McDermott and M. B. Atkins More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma J. Clin. Oncol., September 1, 2007; 25(25): 3791 - 3793. [Full Text] [PDF]

				W. S. Webster, R. H. Thompson, K. J. Harris, X. Frigola, S. Kuntz, B. A. Inman, and H. Dong Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine J. Immunol., September 1, 2007; 179(5): 2860 - 2869. [Abstract] [Full Text] [PDF]

				S. Wei, I. Kryczek, R. P. Edwards, L. Zou, W. Szeliga, M. Banerjee, M. Cost, P. Cheng, A. Chang, B. Redman, et al. Interleukin-2 Administration Alters the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma Cancer Res., August 1, 2007; 67(15): 7487 - 7494. [Abstract] [Full Text] [PDF]

				Y. Kato, K. Yoshimura, T. Shin, H. Verheul, H. Hammers, T. B. Sanni, B. C. Salumbides, K. Van Erp, R. Schulick, and R. Pili Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma Clin. Cancer Res., August 1, 2007; 13(15): 4538 - 4546. [Abstract] [Full Text] [PDF]

				M. Beyer and J. L. Schultze CD4+CD25highFOXP3+ Regulatory T Cells in Peripheral Blood Are Primarily of Effector Memory Phenotype J. Clin. Oncol., June 20, 2007; 25(18): 2628 - 2630. [Full Text] [PDF]

				G. Cesana and H. L. Kaufman In Reply J. Clin. Oncol., June 20, 2007; 25(18): 2630 - 2632. [Full Text] [PDF]

				S. A. Perez, M. V. Karamouzis, D. V. Skarlos, A. Ardavanis, N. N. Sotiriadou, E. G. Iliopoulou, M. L. Salagianni, G. Orphanos, C. N. Baxevanis, G. Rigatos, et al. CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients Clin. Cancer Res., May 1, 2007; 13(9): 2714 - 2721. [Abstract] [Full Text] [PDF]

				G. C. Cesana, F. Romano, G. Piacentini, M. Scotti, A. Brenna, G. Bovo, M. Vaghi, G. Aletti, R. Caprotti, H. Kaufman, et al. Low-dose Interleukin-2 Administered Pre-operatively to Patients with Gastric Cancer Activates Peripheral and Peritumoral Lymphocytes But Does Not Affect Prognosis Ann. Surg. Oncol., April 1, 2007; 14(4): 1295 - 1304. [Abstract] [Full Text] [PDF]

				S. A. Siddiqui, X. Frigola, S. Bonne-Annee, M. Mercader, S. M. Kuntz, A. E. Krambeck, S. Sengupta, H. Dong, J. C. Cheville, C. M. Lohse, et al. Tumor-Infiltrating Foxp3-CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma Clin. Cancer Res., April 1, 2007; 13(7): 2075 - 2081. [Abstract] [Full Text] [PDF]

				H. J.J. van derVliet, H. B. Koon, S. C. Yue, B. Uzunparmak, V. Seery, M. A. Gavin, A. Y. Rudensky, M. B. Atkins, S. P. Balk, and M. A. Exley Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2100 - 2108. [Abstract] [Full Text] [PDF]

				Y. Dang, K. L. Knutson, V. Goodell, C. dela Rosa, L. G. Salazar, D. Higgins, J. Childs, and M. L. Disis Tumor Antigen-Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming Clin. Cancer Res., March 15, 2007; 13(6): 1883 - 1891. [Abstract] [Full Text] [PDF]

				C. Fozza, E. Nadal, M. Longinotti, and F. Dazzi T-cell receptor repertoire usage after allografting differs between CD4+CD25+ regulatory T cells and their CD4+CD25 counterpart Haematologica, February 1, 2007; 92(2): 206 - 214. [Abstract] [Full Text] [PDF]

				J. Vieweg, Z. Su, P. Dahm, and S. Kusmartsev Reversal of Tumor-Mediated Immunosuppression Clin. Cancer Res., January 15, 2007; 13(2): 727s - 732s. [Abstract] [Full Text] [PDF]

				I. Goldstein, S. Ben-Horin, A. Koltakov, H. Chermoshnuk, V. Polevoy, Y. Berkun, N. Amariglio, and I. Bank {alpha}1beta1 Integrin+ and Regulatory Foxp3+ T Cells Constitute Two Functionally Distinct Human CD4+ T Cell Subsets Oppositely Modulated by TNF{alpha} Blockade J. Immunol., January 1, 2007; 178(1): 201 - 210. [Abstract] [Full Text] [PDF]

				P. Hoffmann, R. Eder, T. J. Boeld, K. Doser, B. Piseshka, R. Andreesen, and M. Edinger Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion Blood, December 15, 2006; 108(13): 4260 - 4267. [Abstract] [Full Text] [PDF]

				G. Markel, R. Seidman, N. Stern, T. Cohen-Sinai, O. Izhaki, G. Katz, M. Besser, A. J. Treves, R. S. Blumberg, R. Loewenthal, et al. Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by the Homophilic Carcinoembryonic Cell Adhesion Molecule 1 Interactions J. Immunol., November 1, 2006; 177(9): 6062 - 6071. [Abstract] [Full Text] [PDF]

				E. Zorn, E. A. Nelson, M. Mohseni, F. Porcheray, H. Kim, D. Litsa, R. Bellucci, E. Raderschall, C. Canning, R. J. Soiffer, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo Blood, September 1, 2006; 108(5): 1571 - 1579. [Abstract] [Full Text] [PDF]

				C. Dejaco, C. Duftner, and M. Schirmer Induction of Tolerance in Autoimmune Diseases Rather Than Cure of Cancer by Interleukin-2 Therapy J. Clin. Oncol., July 10, 2006; 24(20): e34 - e34. [Full Text] [PDF]

				G. Cesana, S. Kim-Schulze, and H. L. Kaufman In Reply J. Clin. Oncol., July 10, 2006; 24(20): e35 - e36. [Full Text] [PDF]

				M. B. Atkins Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin. Cancer Res., April 1, 2006; 12(7): 2353s - 2358s. [Abstract] [Full Text] [PDF]